Expertise in
10
conditions

Andreas Engert

Kerpener Str. 62, 50924, 
Koeln, NW, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
10
conditions
Kerpener Str. 62, 50924, 
Koeln, NW, DE 

Overview

Andreas Engert practices practicing medicine in Koeln, Germany.

Mr. Engert is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL), Mediastinal Tumor, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 269 peer reviewed articles and participating in 6 clinical trials.

Gender

Male

Locations

Kerpener Str. 62, 50924, Koeln, NW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma
Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma
Enrollment Status: Recruiting
Publish Date: July 26, 2024
Intervention Type: Drug
Study Drug: Tislelizumab
Study Phase: Phase 2
Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma
Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: March 05, 2026
Intervention Type: Drug
Study Drug: Brentuximab
Study Phase: Phase 2
Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy
Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 03, 2025
Intervention Type: Other
Study Drug: Nivolumab
Study Phase: Phase 2
Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)
Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)
Enrollment Status: Completed
Publish Date: April 08, 2021
Intervention Type: Drug
Study Drug: Ibrutinib
Study Phase: Phase 2
GHSG-AFM13 An Open-label, Randomized, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma
GHSG-AFM13 An Open-label, Randomized, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: November 13, 2020
Intervention Type: Drug
Study Phase: Phase 2
HD17 for Intermediate Stages - Treatment Optimization Trial in the First-Line Treatment of Intermediate Stage Hodgkin Lymphoma
HD17 for Intermediate Stages - Treatment Optimization Trial in the First-Line Treatment of Intermediate Stage Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: April 06, 2020
Intervention Type: Drug, Radiation
Study Phase: Phase 3
View 5 Less Clinical Trials

269 Total Publications

Correlation between progression-free and overall survival in patients with Hodgkin lymphoma: a comprehensive analysis of individual patient data from randomized German Hodgkin Study Group (GHSG) trials.
Correlation between progression-free and overall survival in patients with Hodgkin lymphoma: a comprehensive analysis of individual patient data from randomized German Hodgkin Study Group (GHSG) trials.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: June 04, 2024

Frequently Asked Questions about Andreas Engert

Is Andreas Engert a top-rated expert for Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Andreas Engert is classified as an Elite expert for Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Andreas Engert participate in research or clinical trials?

Yes. Andreas Engert has published 269 articles and abstracts on conditions like Hodgkin Lymphoma. You can view a list of Andreas Engert's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Engert's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 16 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile